Featured Research

from universities, journals, and other organizations

Lupus drugs carry no significant cancer risk for patients, study suggests

Date:
January 24, 2013
Source:
McGill University Health Centre
Summary:
People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer risk according to new research. This study addresses long-standing fears of a link between lupus medication and cancer.

People who take immunosuppressive drugs to treat lupus do not necessarily increase their cancer riskaccording to new research led by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC). This landmark study, which was published in Annals of the Rheumatic Diseases this month, addresses long-standing fears of a link between lupus medication and cancer.

Systemic lupus erythematosus (SLE), commonly known as lupus, is an autoimmune disease in which the body's immune system attacks healthy tissue such as the skin, joints, kidneys and the brain, leading to inflammation and lesions. The disease affects about 1 in 2000 Canadians, particularly women. Previous research has suggested that lupus patients have an increased risk of developing cancer, particularly lymphoma. Lymphoma is a type of blood cancer that occurs when cells called lymphocytes, which usually help protect the body from infection and disease, begin growing and multiplying uncontrollably leading to tumor growth.

"Treatment for Lupus consists largely of immunosuppressive medications, which lower the body's immune response," explains Dr. Sasha Bernatsky, first and corresponding author of the study, who is a researcher within the Divisions of Clinical Epidemiology and Rheumatology at the RI-MUHC and at McGill University.

According to Dr. Ann E. Clarke, director of the MUHC lupus clinic and study co-lead, the fear of developing cancer among Lupus patients has been so great that some were reluctant to take their medication and others stopped altogether.

The international study involved 75 lupus patients with lymphoma from different centres around the world and nearly 5,000 cancer-free lupus patients as a control. Researchers studied most of the drugs commonly used to treat SLE including cyclophosphamide, a drug reserved for severe lupus cases and other chronic inflammatory rheumatic diseases.

The results showed that the risk for lymphoma in lupus patients exposed to cyclophosphamide was less than 0.1% per year. In addition, no clear association was observed between lupus disease activity and lymphoma risk.

"People have been wondering for a long time whether the medications were to blame and the results are reassuring, suggesting that most lymphoma cases in SLE are not triggered by drug exposures," says Dr. Bernatsky.

"This is very good news that cancer risk associated with lupus medication is relatively low," said Louise Bergeron, who has been living with lupus for 12 years. "It reassures me, especially if I need to take more effective immunosuppressive treatments in the coming years."

Future research will focus on the genetic profiles of lupus patients and what impact that can have on the interaction between medication exposure and lymphoma risk in lupus.


Story Source:

The above story is based on materials provided by McGill University Health Centre. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Bernatsky, R. Ramsey-Goldman, L. Joseph, J.-F. Boivin, K. H. Costenbader, M. B. Urowitz, D. D. Gladman, P. R. Fortin, O. Nived, M. A. Petri, S. Jacobsen, S. Manzi, E. M. Ginzler, D. Isenberg, A. Rahman, C. Gordon, G. Ruiz-Irastorza, E. Yelin, S.-C. Bae, D. J. Wallace, C. A. Peschken, M. A. Dooley, S. M. Edworthy, C. Aranow, D. L. Kamen, J. Romero-Diaz, A. Askanase, T. Witte, S. G. Barr, L. A. Criswell, G. K. Sturfelt, I. Blanco, C. H. Feldman, L. Dreyer, N. M. Patel, Y. St Pierre, A. E. Clarke. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Annals of the Rheumatic Diseases, 2013; DOI: 10.1136/annrheumdis-2012-202099

Cite This Page:

McGill University Health Centre. "Lupus drugs carry no significant cancer risk for patients, study suggests." ScienceDaily. ScienceDaily, 24 January 2013. <www.sciencedaily.com/releases/2013/01/130124134044.htm>.
McGill University Health Centre. (2013, January 24). Lupus drugs carry no significant cancer risk for patients, study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/01/130124134044.htm
McGill University Health Centre. "Lupus drugs carry no significant cancer risk for patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2013/01/130124134044.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins